A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
Lyell Immunopharma, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
Orca Biosystems, Inc.
University of Southern California
National Institutes of Health Clinical Center (CC)